CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an appropriate CD20 protein on the market for detecting the CD20-CAR expression and the bioactivity of antibody drugs.
To tackle these challenges, ACROBiosystems has designed the full-length multi-transmembrane CD20 proteins, produced by HEK293 cells and insect cells. The bioactivity and purity of the full-length CD20 protein were confirmed by ELISA, SDS-PAGE, and SPR. In addition, ACROBiosystems provides full-length CD20 protein for immunization and assessment of CD20-CAR expression.
Application
Product List
| Molecule |
Cat. No. |
Host |
Product Description |
| CD20/ MS4A1 |
CD0-H52H3 |
HEK293 |
Human CD20/ MS4A1 Full Length Protein, His Tag |
| CD0-H55Ha |
Insect cells-HI5 |
Human CD20/ MS4A1 Full Length Protein, His Tag |
Product Features
Full-length CD20 protein fully complies with both small and big loops.
Image Credit: ACROBiosystems
Full-length CD20 protein has better bioactivity.
- HEK293 Cell (Full Length)
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL. Image Credit: ACROBiosystems
- Insect Cell (Full Length)
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL. Image Credit: ACROBiosystems
- Escherichia coli (Extracellular)
Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E. coli) with a linear range of 78–2500 ng/mL. Image Credit: ACROBiosystems
The bioactivity of Full-Length CD20 Protein was verified by Elisa/SPR and the protocols are presented.
ELISA
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).
Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL. Image Credit: ACROBiosystems
Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313–1.25 μg/mL. Image Credit: ACROBiosystems
Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL. Image Credit: ACROBiosystems
SPR
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).
MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems
Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems
MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200). Image Credit: ACROBiosystems
Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems
About ACROBiosystems
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.